pharmaphorum

After Pluvicto: Alpha radiopharma and prostate cancer

There are around 46,000 new cases of prostate cancer each year in England and Wales, with 13% of these cases showing signs of ...

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with ...
The American Journal of Managed Care

Meta-Analysis: Pluvicto Extends PFS in Advanced Prostate Cancer Without Adding Toxicity

Pooled trials show Pluvicto improves progression-free survival in advanced prostate cancer, without increasing serious adverse events. An examination of data from more than 2500 patients with advanced ...
Fierce Biotech

ASCO: Telix tees up pivotal test for Pluvicto challenger while eyeing ‘white space’ on radiopharma canvas

After abandoning plans for a Nasdaq IPO back in 2024, Telix made a concerted effort to bolster its radiopharma prowess, ...
STAT

Pluvicto pushes earlier in prostate cancer play

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The American Journal of Managed Care

Adding Radioligand Therapy Pluvicto to SOC Cuts Risk of Prostate Cancer Progression or Death 28%, but How Many Doses?

177Lu-PSMA-617 combined with ADT and ARPI reduced progression or death risk by 28% in PSMA-positive mHSPC patients. The PSMAddition trial showed significant rPFS improvement and a positive OS trend, ...
Insider Monkey

Novartis’ Pluvicto Shows Promise in Early Stage Prostate Cancer

On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu) vipivotide ...
Medscape

Pluvicto vs ARPI in Prostate Cancer: Is One Better?

Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...
Morningstar

Novartis's Cancer Treatment Pluvicto Shows Positive Results in Trial

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...

Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study

Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed ...
WZZM

Chemotherapy alternative offered for prostate cancer patients in Grand Rapids

GRAND RAPIDS, Mich. — One in eight men will be diagnosed with prostate cancer in their lifetime. Typically, treatment includes hormone medication, and when that fails, chemotherapy. BAMF Health in ...

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

The metastatic prostate cancer market is undergoing a major transition from conventional ADT toward combination-based, biomarker-driven, and precision-targeted treatment approaches. While AR pathway ...